Rebecca J Schmidt1,2, Qiaojuan Niu3, Darryl W Eyles4, Robin L Hansen2,5, Ana-Maria Iosif1,2. 1. Department of Public Health Sciences, School of Medicine, University of California, Davis, Davis, California. 2. The MIND Institute, School of Medicine, University of California, Davis, Sacramento, California. 3. Graduate Group in Biostatistics, University of California, Davis, Davis, California. 4. Queensland Centre for Mental Health Research, and Queensland Brain Institute, University of Queensland, St Lucia, Queensland, Australia. 5. Department of Pediatrics, School of Medicine, University of California, Davis, Sacramento, California.
Abstract
Vitamin D appears essential for normal neurodevelopment and cognitive and behavioral function. We examined neonatal vitamin D in relation to the child's later diagnosis of autism spectrum disorder (ASD) or developmental delay (DD). Children aged 24-60 months enrolled in the population-based CHARGE case-control study were evaluated clinically for ASD (n = 357), DD (n = 134), or typical development (TD, n = 234) at the MIND Institute (Sacramento, CA) using standardized assessments. Total 25-hydroxyvitamin D (25[OH]D) was measured using sensitive isotope dilution liquid chromatography-tandem mass spectrometry in archived dried blood spots collected for the California Department of Public Health's Newborn Screening Program. Multinomial logistic regression was used to calculate ORs as measures of the associations between 25 nmol/L change in 25(OH)D and ASD and DD. Associations between 25(OH)D and scores on Mullen Scales of Early Learning and Vineland Adaptive Behavior Scales were assessed using robust linear regression. Effect modification was examined using stratified models and interaction product terms. Unadjusted mean (SD) 25(OH)D was lower for DD (73.2 [37.6]) than for TD (82.7 [39.3]) and ASD (80.1 [37.4]). After adjustment for maternal prepregnancy body mass index and education, a 25 nmol/L increase in total 25(OH)D was not associated with ASD (OR = 0.97; CI: 0.87-1.08) or DD (OR = 0.91; 95% CI: 0.78-1.06). Neonatal 25(OH)D was associated with significantly reduced ASD only in females (adjusted OR = 0.74; 95% CI: 0.55-0.99, Pinteraction = 0.03), and significantly reduced DD only in non-Hispanic white children (adjusted OR = 0.79; 95% CI: 0.63-0.98, Pinteraction = 0.11 for Hispanic, Pinteraction = 0.31 for other), driven by DD children with trisomy 21. This study provides evidence that neonatal vitamin D could be associated with ASD in females and with DD in non-Hispanic white children. Autism Res 2019, 12: 976-988.
Vitamin D appears essential for normal neurodevelopment and cognitive and behavioral function. We examined neonatal vitamin D in relation to the child's later diagnosis of autism spectrum disorder (ASD) or developmental delay (DD). Children aged 24-60 months enrolled in the population-based CHARGE case-control study were evaluated clinically for ASD (n = 357), DD (n = 134), or typical development (TD, n = 234) at the MIND Institute (Sacramento, CA) using standardized assessments. Total 25-hydroxyvitamin D (25[OH]D) was measured using sensitive isotope dilution liquid chromatography-tandem mass spectrometry in archived dried blood spots collected for the California Department of Public Health's Newborn Screening Program. Multinomial logistic regression was used to calculate ORs as measures of the associations between 25 nmol/L change in 25(OH)D and ASD and DD. Associations between 25(OH)D and scores on Mullen Scales of Early Learning and Vineland Adaptive Behavior Scales were assessed using robust linear regression. Effect modification was examined using stratified models and interaction product terms. Unadjusted mean (SD) 25(OH)D was lower for DD (73.2 [37.6]) than for TD (82.7 [39.3]) and ASD (80.1 [37.4]). After adjustment for maternal prepregnancy body mass index and education, a 25 nmol/L increase in total 25(OH)D was not associated with ASD (OR = 0.97; CI: 0.87-1.08) or DD (OR = 0.91; 95% CI: 0.78-1.06). Neonatal 25(OH)D was associated with significantly reduced ASD only in females (adjusted OR = 0.74; 95% CI: 0.55-0.99, Pinteraction = 0.03), and significantly reduced DD only in non-Hispanic white children (adjusted OR = 0.79; 95% CI: 0.63-0.98, Pinteraction = 0.11 for Hispanic, Pinteraction = 0.31 for other), driven by DD children with trisomy 21. This study provides evidence that neonatal vitamin D could be associated with ASD in females and with DD in non-Hispanic white children. Autism Res 2019, 12: 976-988.
Authors: Laura A G Armas; Susan Dowell; Mohammed Akhter; Sowjanya Duthuluru; Christopher Huerter; Bruce W Hollis; Richard Lund; Robert P Heaney Journal: J Am Acad Dermatol Date: 2007-07-16 Impact factor: 11.527
Authors: Lisa M Bodnar; Hyagriv N Simhan; Robert W Powers; Michael P Frank; Emily Cooperstein; James M Roberts Journal: J Nutr Date: 2007-02 Impact factor: 4.798
Authors: Irva Hertz-Picciotto; Lisa A Croen; Robin Hansen; Carrie R Jones; Judy van de Water; Isaac N Pessah Journal: Environ Health Perspect Date: 2006-07 Impact factor: 9.031
Authors: Kristen Lyall; Jennifer L Ames; Michelle Pearl; Michela Traglia; Lauren A Weiss; Gayle C Windham; Martin Kharrazi; Cathleen K Yoshida; Robert Yolken; Heather E Volk; Paul Ashwood; Judy Van de Water; Lisa A Croen Journal: Mol Autism Date: 2021-03-18 Impact factor: 7.509
Authors: Agnes M Mutua; Margaret Nampijja; Alison M Elliott; John M Pettifor; Thomas N Williams; Amina Abubakar; Emily L Webb; Sarah H Atkinson Journal: Nutrients Date: 2020-06-03 Impact factor: 6.706
Authors: Amina Abubakar; Sarah H Atkinson; Agnes M Mutua; Reagan M Mogire; Alison M Elliott; Thomas N Williams; Emily L Webb Journal: Wellcome Open Res Date: 2020-06-11